Fintel reports that on October 31, 2025, HC Wainwright & Co. maintained coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) ...

(Alliance News) - RTW Biotech Opportunities Ltd on Friday confirmed it has entered into a royalty funding agreement with clinical stage biopharmaceutical company Savara Inc for a rare lung disease ...

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

How a US SOL ETF could shift access, flows and usage — plus the key metrics to watch to see whether Solana outperforms Ether. ETH ETFs have opened access, but flows remain cyclical. SOL’s plumbing is ...

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On ...

Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp ...

Investors piled $142 billion into US ETFs in September. That’s the best month so far this year and $53 billion more than last September’s tally. Active ETFs accounted for 35% of inflows, with the ...

The VanEck Pharmaceutical exchange-traded fund is on a strong run this week as news of Pfizer's deal with the Trump administration helped boost pharmaceutical stocks. The ETF was up 1.1% at $94.36 in ...